Yogen Saunthararajah
Overview
Explore the profile of Yogen Saunthararajah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
3758
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica R, et al.
Blood
. 2024 Sep;
144(22):2360-2363.
PMID: 39316768
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for...
2.
Saunthararajah Y
J Clin Invest
. 2024 Apr;
134(8).
PMID: 38618954
Cell and antibody therapies directed against surface molecules on B cells, e.g., CD19-targeting chimeric antigen receptor T cells (CD19 CAR-T), are now standard for patients with chemorefractory B cell acute...
3.
Woost P, William B, Cooper B, Ueda Oshima M, Otegbeye F, De Lima M, et al.
Cytometry B Clin Cytom
. 2024 Feb;
106(1):11-24.
PMID: 38345160
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic...
4.
Biswas S, Kang K, Ng K, Radivoyevitch T, Schalper K, Zhang H, et al.
Cell Rep
. 2023 Aug;
42(8):113016.
PMID: 37597186
Small cell lung cancers (SCLCs) rapidly resist cytotoxic chemotherapy and immune checkpoint inhibitor (ICI) treatments. New, non-cross-resistant therapies are thus needed. SCLC cells are committed into neuroendocrine lineage then maturation...
5.
Lau H, Woost P, Friedrich U, Clausen W, Jacobberger J, Saunthararajah Y
Eur J Haematol
. 2023 Jul;
111(3):345-355.
PMID: 37417197
Background: Sickle cell disease (SCD) is caused by an inherited structural abnormality of adult hemoglobin causing polymerization. Fetal hemoglobin interferes with polymerization but is epigenetically silenced by DNA methyltransferase 1...
6.
Karan D, Singh M, Dubey S, Van Veldhuizen P, Saunthararajah Y
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345101
Epigenetic alterations such as DNA methylation and histone modifications are implicated in repressing several tumor suppressor genes in prostate cancer progression. In this study, we determined the anti-prostate cancer effect...
7.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro L, Mantzaris I, Shastri A, et al.
Clin Cancer Res
. 2023 Jun;
29(15):2774-2780.
PMID: 37341641
Purpose: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for elderly patients with acute myeloid leukemia (AML) and is being evaluated...
8.
Ibanez V, Vaitkus K, Zhang X, Ramasamy J, Rivers A, Saunthararajah Y, et al.
Blood Adv
. 2023 Mar;
7(15):3891-3902.
PMID: 36884303
Increased fetal hemoglobin (HbF) levels reduce the symptoms of sickle cell disease (SCD) and increase the lifespan of patients. Because curative strategies for bone marrow transplantation and gene therapy technologies...
9.
Gomez S, Cox O, Walker 3rd R, Rentia U, Hadley M, Arthofer E, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36343976
Background: Novel therapies are urgently needed for ovarian cancer (OC), the fifth deadliest cancer in women. Preclinical work has shown that DNA methyltransferase inhibitors (DNMTis) can reverse the immunosuppressive tumor...
10.
von Knebel Doeberitz N, Paech D, Sturm D, Pusch S, Turcan S, Saunthararajah Y
Int J Cancer
. 2022 May;
151(9):1431-1446.
PMID: 35603902
Glial-lineage malignancies (gliomas) recurrently mutate and/or delete the master regulators of apoptosis p53 and/or p16/CDKN2A, undermining apoptosis-intending (cytotoxic) treatments. By contrast to disrupted p53/p16, glioma cells are live-wired with the...